Anavex HISTORISKE OG BANEBRYDENDE RESULTATER I ALZHEIMER!!!
-
Seeking Alpha i dag: Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved
https://seekingalpha.com/article/4573554-approval-for-anavex-blarcamesine-looks-inevitable -
Anavex Q1 rapport tirsdag den 7. feb. 2023.
Webcast kl. 14.30 DK-tid.
Management will host a conference call on Tuesday February 7, 2023, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following management's remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
Management will host a conference call on Tuesday February 7, 2023, at 8:30 am ET. The live webcast of the conference call will be available on Anavex's website at www.anavex.com.
-
Anavex Black Rock øger andel i Anavex - nu 7,2 %!
- 500.000 aktier - nu 5.578.159 - via. en 13G.
Men stort set alle andre og nye "institutionals" har øget eller startet en position - går lodret mod antallet af shortpositioner er øget til godt 18 mill. i samme periode!
Vi må se hvem der får ret, men det er højst usædvanligt med en så voldsom modsatrettet syn på investeringen - det kan næsten kun ende med et brag - læs short squeeze! -
Udviklingen er interessant og kursen er noget følsom.
Jeg kan godt sidde med fornemmelsen af, at nogen (måske den store sorte sten) styrede markedskursen og skulle have en lavere GAK på sin position - inden et muligt gennembrud eksekveres.
Mit syn er kombineret af opportunisme og kursanalyse.
Er det en klassisk "ryste-træet-opgave" vi så udført?
-
For min skynd må Torben gerne vente forgæves
dog med håbet om det bedste.Hvor kursen skal hen er jeg lidt indifferent overfor. Jeg spejder efter data og regner med, at det sætter den overordnede retning på6 kursdannelsen.
Make it or break it
-
Beklager, hvis den er lidt off-topic i denne AD-tråd: https://www.globenewswire.com/news-release/2023/02/02/2600303/29248/en/Anavex-Life-Sciences-Announces-Exceeding-of-Enrollment-Target-for-the-ANAVEX-2-73-blarcamesine-EXCELLENCE-Phase-2-3-Rett-Syndrome-Clinical-Trial.html
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX
2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial -
Anavex EXCELLENCE fase 2/3 Rett har afsluttet indrulning af 92 patienter - 8 flere end udgangspunktet.
Data 2. halvår 2023. (12 uger forsøg + 4-5 mdr. analyse) -
Skal vi sige langt om længe
Færdig om ca 12 uger så omkring juli 2023 kan vi forvente data fra de relativt få pts - 84 stk
Anavex har udtalt noget der kunne lyde som rolling submission af de data de allerede har i rett. Derfor skal vi nok ikke langt ind i 2024 før en approval kan komme. Evt. 100 mln i usd for en voucher kan også komme her, hvis ikke AD er godkendt inden.
Spændende at se data i de stakkels børn med rett. Tror Blarcamesine giver en bedre hverdag for dem !!!
-
Anavex HC Wainwright gentager kursmål 50 $
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $50 Price Target - Anavex Life Scie
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $50 price target.
Benzinga (www.benzinga.com)
-
Anavex Ny IR ansat - trænger hårdt til bedre kommunikation til aktionærerne.
IR har i den grad behov for et løft, men de kan selvfølgelig heller ikke kommunikerer mere og andet ud, end det ledelsen ønsker.
Husk Q1 rapport i morgen tirsdag den 7. feb. 2023.
Webcast kl. 14.30 DK-tid.Lidt unormalt med webcast før markedet åbner. Anavex afholder normalt disse kvartalsrapporter efter markedet er lukke kl. 22.30 - DK-tid.
- der behøver dog ikke at være noget særligt i det og q-rapport er sædvanligvis et non-event - det kan dog være noget mellem linjerne og svar fra analytikerne, som kan fortæller lidt interessant ting.
Tror der arbejdes i vildskab på flere planer bag scenen!
Øges aktiviteten giver det udmærket mening med en styrkelse af IR og kommunikation.
Luke Brown
Capital Markets and IR Professional
New York, New York, USA
1 t følgere 500+ forbindelser
Tilmeld dig for at se profilen
Anavex Life Sciences
Anavex Life Sciences
Crummer Graduate School of Business at Rollins College
Crummer Graduate School of Business at Rollins CollegeOm
From the start of my career, I have consulted with executives and contributed to successfully meeting their goals, regardless of size and scope . From enhancing investor relation programs to bringing companies public, I've worked with the entire ecosystem of advisors, lawyers, bankers, trade groups and investors (PE, VC & mutual funds managers) to ensure my customers' needs are met. My clients have ranged in size from seed stage to public mega caps across the healthcare sector and have touched the energy, tech and consumer spaces.I lean into my interpersonal skills to develop relationships and have a deep rolodex of contacts across The Street. My strong analytical and technical skills compliment my ability to maintain personal relationships with key players and founding CEOs.
My written and face-to-face communication skills are a positive while my Excel and Powerpoint top-quality.
Luke Brown - Ropes & Gray LLP | LinkedIn
From the start of my career, I have consulted with executives and contributed to… · Experience: Ropes & Gray LLP · Education: Crummer Graduate School of Business at Rollins College · Location: New York · 500+ connections on LinkedIn. View Luke Brown’s profile on LinkedIn, a professional community of 1 billion members.
(www.linkedin.com)
- der behøver dog ikke at være noget særligt i det og q-rapport er sædvanligvis et non-event - det kan dog være noget mellem linjerne og svar fra analytikerne, som kan fortæller lidt interessant ting.
-
-
Key Near Term Pipeline Updates:
Alzheimer's disease: Full data ANAVEX2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trialParkinson's disease dementia: Data of 48-week OLE Phase 2 study
Parkinson's disease: Initiation of ANAVEX
2-73 imaging-focused clinical trialFragile X: Initiation of potentially pivotal ANAVEX
2-73 Phase 2/3 clinical trialSchizophrenia: Initiation of ANAVEX
3-71 Phase 2 clinical trialNew Rare disease: Initiation of potentially pivotal ANAVEX
2-73 Phase 2/3 clinical trialPublications: Several clinical publications involving ANAVEX
2-73, ANAVEX3-71 and Rett syndrome Burden of Illness study
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind